‘Financial fallout’ in the US biopharmaceutical industry: Maximizing shareholder value, regulatory capture, and the consequences for patients
Author:
Open Access
- 23 January 2024
- journal article
- research article
- Published by Elsevier in Social Science & Medicine
- Vol. 344, 116598
Abstract
No abstract availableKeywords
Funding Information
- Swiss National Science Foundation
This publication has 31 references indexed in Scilit:
- Assessing the ‘relative value’ of diabetic patients treated through an incentivized, corporate compliance modelAnthropology & Medicine, 2010
- Making Longevity in an Aging Society: Linking Medicare Policy and the New Ethical FieldPerspectives in Biology and Medicine, 2010
- “Stains” on their self‐discipline: Public health, hygiene, and the disciplining of undocumented immigrant parents in the nation's internal borderlandsAmerican Ethnologist, 2009
- The revenge of the market on the rentiers.: Why neo-liberal reports of the end of history turned out to be prematureCambridge Journal of Economics, 2009
- Shifting Subject PositionsSocial Studies of Science, 2007
- The financialization of the American economySocio-Economic Review, 2005
- Evidence-Based Medicine In The United States—De Rigueur Or Dream Deferred?Health Affairs, 2005
- Why Medicare Has Not Established Criteria for Coverage DecisionsNew England Journal of Medicine, 2004
- The Politics of Life ItselfTheory, Culture & Society, 2001
- Transforming the Safety Net: Responses to Medicaid Managed Care in, Rural and Urban New MexicoAmerican Anthropologist, 2001